Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
25. Februar 2021 02:00 ET
|
Verona Pharma plc
Positive Phase 2 results with pMDI ensifentrine in COPD Enrollment ongoing in ENHANCE Phase 3 program Up to $30 million debt finance facility increases financial flexibility Conference...
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
18. Februar 2021 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
02. Februar 2021 06:17 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the unit...
Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
02. Februar 2021 02:00 ET
|
Verona Pharma plc
Primary and secondary lung function endpoints met Results support twice-daily dosing LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”),...
Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
14. Januar 2021 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
05. Januar 2021 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
23. November 2020 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Announces November 2020 Virtual Investor Conference Participation
09. November 2020 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
29. Oktober 2020 03:00 ET
|
Verona Pharma plc
Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot clinical study in U.S. patients hospitalized with COVID-19 ...
Verona Pharma plc : Update on AIM Delisting
28. Oktober 2020 07:01 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intended...